title: Cutaneous manifestations of nontargeted and targeted chemotherapies.
abstract: Care of the oncologic patient requires an integral understanding of the adverse reactions of chemotherapy. With the advent of targeted agents and immunomodulating therapies, reactions to these newer treatments are of clinical interest. Cutaneous side effects of chemotherapeutic agents, including toxic erythema and mucositis, are common and may require cessation of treatment if associated with discomfort, superinfection, or negative impact on quality of life. This article reviews the cutaneous adverse reactions and treatment options of both conventional cytotoxic chemotherapeutic agents and newer targeted, multikinase inhibitors and immunomodulating therapies. An understanding of possible cutaneous reactions by all providers involved in the care of the oncologic patient is critical for prompt recognition, allowing for appropriate treatment and referral to dermatologists when necessary.
authors.affiliation: Department of Dermatology, Yale University School of Medicine, New Haven, CT.
authors.forename: Veronica J
authors.initials: VJ
authors.lastname: Shi
authors.affiliation: Department of Dermatology, Yale University School of Medicine, New Haven, CT.
authors.forename: Lauren L
authors.initials: LL
authors.lastname: Levy
authors.affiliation: Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IL. Electronic address: jennifer.choi@nm.org.
authors.forename: Jennifer N
authors.initials: JN
authors.lastname: Choi
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D004890:Erythema / Q000139:chemically induced; D006801:Humans; D007167:Immunotherapy / Q000009:adverse effects* / Q000379:methods; D020930:MAP Kinase Kinase Kinases / Q000037:antagonists & inhibitors; D058990:Molecular Targeted Therapy / Q000009:adverse effects* / Q000379:methods; D052016:Mucositis / Q000139:chemically induced; D009262:Nails / Q000187:drug effects; D048493:Proto-Oncogene Proteins B-raf / Q000037:antagonists & inhibitors
chemical_list: D000970:Antineoplastic Agents; C512478:EGFR protein, human; D066246:ErbB Receptors; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf; D020930:MAP Kinase Kinase Kinases
keywords: Cutaneous adverse reactions; Cytotoxic chemotherapy; Immunotherapy; Multikinase inhibitors; Targeted chemotherapy; Toxic erythema